vs
EXACT SCIENCES CORP（EXAS）与Life Time Group Holdings, Inc.（LTH）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Life Time Group Holdings, Inc.的1.2倍（$878.4M vs $745.1M），Life Time Group Holdings, Inc.净利率更高（16.5% vs -9.8%，领先26.3%），EXACT SCIENCES CORP同比增速更快（23.1% vs 12.3%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $-64.6M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 11.7%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Life Time Group Holdings是美国高端健身康养服务运营商，在全美运营连锁高端运动场馆，提供健身器材使用、团体课程、私教指导、SPA护理、营养咨询、青少年运动项目及联合办公等服务，服务于追求健康生活方式的消费群体。
EXAS vs LTH — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $745.1M |
| 净利润 | $-86.0M | $123.0M |
| 毛利率 | 70.1% | 49.1% |
| 营业利润率 | -9.4% | 17.4% |
| 净利率 | -9.8% | 16.5% |
| 营收同比 | 23.1% | 12.3% |
| 净利润同比 | 90.1% | 231.0% |
| 每股收益（稀释后） | $-0.45 | $0.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $878.4M | $745.1M | ||
| Q3 25 | $850.7M | $782.6M | ||
| Q2 25 | $811.1M | $761.5M | ||
| Q1 25 | $706.8M | $706.0M | ||
| Q4 24 | $713.4M | $663.3M | ||
| Q3 24 | $708.7M | $693.2M | ||
| Q2 24 | $699.3M | $667.8M | ||
| Q1 24 | $637.5M | $596.7M |
| Q4 25 | $-86.0M | $123.0M | ||
| Q3 25 | $-19.6M | $102.4M | ||
| Q2 25 | $-1.2M | $72.1M | ||
| Q1 25 | $-101.2M | $76.1M | ||
| Q4 24 | $-864.6M | $37.2M | ||
| Q3 24 | $-38.2M | $41.4M | ||
| Q2 24 | $-15.8M | $52.8M | ||
| Q1 24 | $-110.2M | $24.9M |
| Q4 25 | 70.1% | 49.1% | ||
| Q3 25 | 68.6% | 47.1% | ||
| Q2 25 | 69.3% | 47.0% | ||
| Q1 25 | 70.8% | 47.5% | ||
| Q4 24 | 69.0% | 48.2% | ||
| Q3 24 | 69.4% | 46.5% | ||
| Q2 24 | 69.8% | 46.8% | ||
| Q1 24 | 70.0% | 46.1% |
| Q4 25 | -9.4% | 17.4% | ||
| Q3 25 | -3.0% | 17.3% | ||
| Q2 25 | -0.3% | 14.2% | ||
| Q1 25 | -13.6% | 15.2% | ||
| Q4 24 | -122.8% | 13.1% | ||
| Q3 24 | -5.6% | 13.5% | ||
| Q2 24 | -3.8% | 15.7% | ||
| Q1 24 | -16.7% | 12.1% |
| Q4 25 | -9.8% | 16.5% | ||
| Q3 25 | -2.3% | 13.1% | ||
| Q2 25 | -0.1% | 9.5% | ||
| Q1 25 | -14.3% | 10.8% | ||
| Q4 24 | -121.2% | 5.6% | ||
| Q3 24 | -5.4% | 6.0% | ||
| Q2 24 | -2.3% | 7.9% | ||
| Q1 24 | -17.3% | 4.2% |
| Q4 25 | $-0.45 | $0.55 | ||
| Q3 25 | $-0.10 | $0.45 | ||
| Q2 25 | $-0.01 | $0.32 | ||
| Q1 25 | $-0.54 | $0.34 | ||
| Q4 24 | $-4.69 | $0.17 | ||
| Q3 24 | $-0.21 | $0.19 | ||
| Q2 24 | $-0.09 | $0.26 | ||
| Q1 24 | $-0.60 | $0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $204.8M |
| 总债务越低越好 | — | $1.5B |
| 股东权益账面价值 | $2.4B | $3.1B |
| 总资产 | $5.9B | $8.0B |
| 负债/权益比越低杠杆越低 | — | 0.48× |
8季度趋势，按日历期对齐
| Q4 25 | $964.7M | $204.8M | ||
| Q3 25 | $1.0B | $218.9M | ||
| Q2 25 | $858.4M | $175.5M | ||
| Q1 25 | $786.2M | $59.0M | ||
| Q4 24 | $1.0B | $10.9M | ||
| Q3 24 | $1.0B | $120.9M | ||
| Q2 24 | $946.8M | $34.5M | ||
| Q1 24 | $652.1M | $18.6M |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $2.0B |
| Q4 25 | $2.4B | $3.1B | ||
| Q3 25 | $2.5B | $3.0B | ||
| Q2 25 | $2.5B | $2.9B | ||
| Q1 25 | $2.4B | $2.7B | ||
| Q4 24 | $2.4B | $2.6B | ||
| Q3 24 | $3.2B | $2.6B | ||
| Q2 24 | $3.2B | $2.4B | ||
| Q1 24 | $3.1B | $2.3B |
| Q4 25 | $5.9B | $8.0B | ||
| Q3 25 | $5.9B | $7.8B | ||
| Q2 25 | $5.8B | $7.6B | ||
| Q1 25 | $5.7B | $7.3B | ||
| Q4 24 | $5.9B | $7.2B | ||
| Q3 24 | $6.7B | $7.2B | ||
| Q2 24 | $6.7B | $7.1B | ||
| Q1 24 | $6.4B | $7.1B |
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.53× | ||
| Q1 25 | — | 0.56× | ||
| Q4 24 | — | 0.59× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.87× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $239.9M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $-64.6M |
| 自由现金流率自由现金流/营收 | 13.7% | -8.7% |
| 资本支出强度资本支出/营收 | 3.6% | 40.9% |
| 现金转化率经营现金流/净利润 | — | 1.95× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $-21.0M |
8季度趋势，按日历期对齐
| Q4 25 | $151.7M | $239.9M | ||
| Q3 25 | $219.9M | $251.1M | ||
| Q2 25 | $89.0M | $195.7M | ||
| Q1 25 | $30.8M | $183.9M | ||
| Q4 24 | $47.1M | $163.1M | ||
| Q3 24 | $138.7M | $151.1M | ||
| Q2 24 | $107.1M | $170.4M | ||
| Q1 24 | $-82.3M | $90.4M |
| Q4 25 | $120.4M | $-64.6M | ||
| Q3 25 | $190.0M | $28.6M | ||
| Q2 25 | $46.7M | $-26.3M | ||
| Q1 25 | $-365.0K | $41.4M | ||
| Q4 24 | $10.7M | $26.8M | ||
| Q3 24 | $112.6M | $64.0M | ||
| Q2 24 | $71.2M | $26.1M | ||
| Q1 24 | $-120.0M | $-66.4M |
| Q4 25 | 13.7% | -8.7% | ||
| Q3 25 | 22.3% | 3.7% | ||
| Q2 25 | 5.8% | -3.5% | ||
| Q1 25 | -0.1% | 5.9% | ||
| Q4 24 | 1.5% | 4.0% | ||
| Q3 24 | 15.9% | 9.2% | ||
| Q2 24 | 10.2% | 3.9% | ||
| Q1 24 | -18.8% | -11.1% |
| Q4 25 | 3.6% | 40.9% | ||
| Q3 25 | 3.5% | 28.4% | ||
| Q2 25 | 5.2% | 29.2% | ||
| Q1 25 | 4.4% | 20.2% | ||
| Q4 24 | 5.1% | 20.6% | ||
| Q3 24 | 3.7% | 12.6% | ||
| Q2 24 | 5.1% | 21.6% | ||
| Q1 24 | 5.9% | 26.3% |
| Q4 25 | — | 1.95× | ||
| Q3 25 | — | 2.45× | ||
| Q2 25 | — | 2.71× | ||
| Q1 25 | — | 2.41× | ||
| Q4 24 | — | 4.39× | ||
| Q3 24 | — | 3.65× | ||
| Q2 24 | — | 3.23× | ||
| Q1 24 | — | 3.63× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
LTH
| Membership | $535.1M | 72% |
| In Center | $191.2M | 26% |
| Other | $18.8M | 3% |
